Abstract:Background: Aberrant chronic inflammation and excess accumulation of lipids play a pivotal role in the occurrence and progression of atherosclerosis. (-)-Epigallocatechin-3-gallate (EGCG), the major catechins in green tea, displayed anti-atherosclerotic properties in vivo and in vitro. However, the effects and underlying mechanism of EGCG on atherosclerosis remain unclear. Methods: Male apolipoprotein E-knockout (ApoE-/-) mice (7 weeks old) fed with high-fat diet (HFD) were treated with normal saline or EGCG (40 mg/kg/d, i.g.) for 18 weeks. Atherosclerotic plaque and liver lipid accumulation were measured by Oil Red staining. Plasma lipids and cytokines were detected using commercial kits. The expression of protein and mRNA was analyzed by western blot and quantitative real-time reverse transcription-polymerase chain reaction, respectively. Results: EGCG administration markedly attenuated atherosclerotic plaque formation in HFD-fed ApoE-/- mice, which were accompanied by increased plasma interleukin-10 (IL-10) level and decreased plasma IL-6 and tumor necrosis factor-α (TNF-α) levels. In addition, EGCG modulated high-fat-induced dyslipidemia, evidencing by decreased total cholesterol (TC) and low-density lipoprotein levels and increased high-density lipoprotein level. Meanwhile, EGCG treatment alleviated high-fat-mediated liver lipid accumulation and decreased liver TC and triglyceride. Mechanistically, EGCG significantly modulated high-fat-induced hepatic tetratricopeptide repeat domain protein 39B (TTC39B) expression and its related genes (Lxrβ, Abcg5, Abcg8, Abca1, Srebf1, Scd1, Scd2, Fas, Elovl5, Mylip) expression in liver from ApoE-/- mice. Notably, EGCG remarkably induced hepatic liver X receptor α (LXRα) and LXRβ expression and inhibited both precursor and mature sterol regulatory element binding transcription factor-1 (SREBP-1) expression. Conclusion: Taken together, our data for the first time suggested that TTC39B was involved in EGCG-mediated anti-atherosclerotic effects through modulation of LXR/SREBP-1 pathway.

(-)- <i>Epicatechin Gallate</i> Interferes with Atherosclerotic Lesions by Inhibiting the Foaming of RAW264.7 Cells Induced by ox-LDL

(-)-Epicatechin gallate blocked cellular foam formation in atherosclerosis by modulating CD36 expression in vitro and in vivo

The Inhibitory Effect of (−)-Epicatechin Gallate on the Proliferation and Migration of Vascular Smooth Muscle Cells Weakens and Stabilizes Atherosclerosis

(-)-Epicatechin gallate prevented atherosclerosis by reducing abnormal proliferation of VSMCs and oxidative stress of AML 12 cells

Epigallocatechin-3-Gallate Inhibits Matrix Metalloproteinase-9 and Monocyte Chemotactic Protein-1 Expression Through the 67-Κda Laminin Receptor and the TLR4/MAPK/NF-κB Signalling Pathway in Lipopolysaccharide-Induced Macrophages

Epigallocatechin-3-gallate Ameliorates LPS-induced Inflammation by Inhibiting the Phosphorylation of Akt and ERK Signaling Molecules in Rat H9c2 Cells

Epigallocatechin gallate (EGCG) inhibits lipopolysaccharide-induced inflammation in RAW 264.7 macrophage cells via modulating nuclear factor kappa-light-chain enhancer of activated B cells (NF- κ B) signaling pathway

Green Tea Polyphenol Epigallocatechin-3-gallate Increases Atherosclerotic Plaque Stability in Apolipoprotein E-deficient Mice Fed a High-Fat Diet

EGCG Attenuates Atherosclerosis Through the Jagged-1/Notch Pathway.

Epigallocatechin-3-gallate Attenuates Lipopolysaccharide-Induced Inflammation in Human Retinal Endothelial Cells

Anti-inflammatory Effects of (-)-epicatechin in Lipopolysaccharide-Stimulated Raw 264.7 Macrophages

(-)-Epigallocatechin-3-Gallate Ameliorates Atherosclerosis and Modulates Hepatic Lipid Metabolic Gene Expression in Apolipoprotein E Knockout Mice: Involvement of TTC39B

Epigallocatechin-3-gallate Prevents TNF-α-induced NF-κB Activation Thereby Upregulating ABCA1 Via the Nrf2/Keap1 Pathway in Macrophage Foam Cells.

Epigallocatechin-3-gallate inhibits H 2 O 2 -induced apoptosis in Mouse Vascular Smooth Muscle Cells via 67kD Laminin Receptor

(−)-Epigallocatechin gallate inhibits endotoxin-induced expression of inflammatory cytokines in human cerebral microvascular endothelial cells

Epigallocatechin Gallate Preserves Endothelial Function by Reducing the Endogenous Nitric Oxide Synthase Inhibitor Level

(-)-Epigallocatechin Gallate Inhibits Endothelin-1-induced C-reactive Protein Production in Vascular Smooth Muscle Cells.

L-theanine Inhibits Foam Cell Formation Via Promoting the Scavenger Receptor A Degradation

Green Tea Epigallocatechin-3-gallate Attenuates Porphyromonas Gingivalis-Induced Atherosclerosis

Inhibition of Emmprin and Mmp-9 Expression by Epigallocatechin-3-Gallate Through 67-Kda Laminin Receptor in Pma-Induced Macrophages

Advances in the Anti-Atherosclerotic Mechanisms of Epigallocatechin Gallate

(-)- &lt;i&gt;Epicatechin Gallate&lt;/i&gt; Interferes with Atherosclerotic Lesions by Inhibiting the Foaming of RAW264.7 Cells Induced by ox-LDL